- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
NEW YORK, USA/LEIPZIG, Germany: Novalar Pharmaceuticals has announced to have chosen Sanofi-Aventis Deutschland as exclusive distributor of their OraVerse anestethia reversal technology in Germany. Sanofi-Aventis, one of the leading German pharmaceutical companies, will also have the option to extend the license to other countries in Europe, both companies said. They intend to launch the product in early 2011.
OraVerse is a local anesthesia reversal agent that is said to accelerate the return of normal sensation and function following routine dental procedures. It is indicated for the reversal of soft tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is indicated for use only in adults and children 6 years of age or older and weighing at least 15 kg.
“As the largest dental market for local anesthetics in Europe, Germany represents a significant opportunity for the introduction of OraVerse,” said Donna Janson, President and Chief Executive Officer at Novalar. “Sanofi-Aventis do not only bring strong brand recognition and expertise in the European regulatory process but also demonstrated success in the dental industry. Their commercial network of will enable rapid penetration and reach into the target market.”
She added that applications for Marketing Authorization in several European countries will be submitted shortly.
Fri. 26 April 2024
12:00 PM EST (New York)
How you can access data-driven decision making
Mon. 29 April 2024
12:30 PM EST (New York)
Root caries: The challenge in today’s cariology
Tue. 30 April 2024
1:00 PM EST (New York)
Neodent Discovery: Neoarch Guided Surgery—from simple to complex cases
Fri. 3 May 2024
1:00 PM EST (New York)
Osseointegration in extrēmus: Complex maxillofacial reconstruction & rehabilitation praeteritum, praesens et futurum
Tue. 7 May 2024
8:00 PM EST (New York)
You got this! Diagnosis and management of common oral lesions
Thu. 9 May 2024
8:00 PM EST (New York)
Empowering your restorative practice: A comprehensive guide to clear aligner integration and success
Mon. 13 May 2024
1:00 PM EST (New York)
To post a reply please login or register